Legislators in Maryland Advance Psychedelic Resear
Post# of 135
(Total Views: 234)
Posted On: 04/19/2022 5:08:06 PM
Legislators in Maryland Advance Psychedelic Research Measure to Governor’s Desk
Last week, legislators in Maryland advanced a measure to the governor that would establish a state fund to provide access to psychedelic drugs such as ketamine, MDMA and psilocybin free of charge to veterans suffering from traumatic brain injury and post-traumatic stress disorder (PTSD).
The measure, which was introduced by Sen. Sarah Elfreth, cleared the House the week before. This comes after its unanimous approval in the Senate in March. This bill would establish a traumatic brain injury and PTSD alternative therapies fund.
In its text, the bill stipulates that the monies from the fund would be used to study alternative therapies that could be used by veterans with traumatic brain injuries and PTSD. The bill adds that the Department of Health in the state will be required to consult with the Walter Reed National Military Medical Center, Sheppard Pratt Hospital, the University of Maryland, Johns Hopkins University and the Department of Veterans Affairs.
The objective of these partnerships would be to find methods of improving access for veterans to alternative therapies for traumatic brain injuries and PTSD, as well as determine the effectiveness of said therapies. The department is required to submit a report to the governor containing initial recommendations and findings by Dec. 1, 2022.
The legislation also includes a separate deadline for recommendations and findings, which would be based on studies that were financed with the fund established by the measure. The measure’s text adds that these recommendations should focus on regulatory, legislative or budgetary changes to improve access to alternative therapies for veterans with traumatic-brain injuries and PTSD. It also asks that the governor include $1 million in an annual budget legislation for the fund, for the 2024 fiscal year.
Maryland is not the only state to advance a psychedelic reform measure in the country during this session, with legislators in Georgia recently passing a bipartisan legislation which demands that a study committee look into the therapeutic potential of psychedelics be formed. The committee will also be required to make recommendations for reform.
Last month, Utah Governor Spencer Cox also signed a measure to establish a task force to conduct research on psychedelics and give recommendations on the therapeutic potential of these drugs as well as possible regulations for their legal use. Additionally, a legislative committee passed a measure in Connecticut last month that would allow the state to offer eligible patients access to psychedelic-assisted therapy with drugs, including psilocybin and MDMA.
Already, companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) have established themselves as leading providers of ketamine treatments, and further research is ongoing to expand to other psychedelics as they become legal in different jurisdictions.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Last week, legislators in Maryland advanced a measure to the governor that would establish a state fund to provide access to psychedelic drugs such as ketamine, MDMA and psilocybin free of charge to veterans suffering from traumatic brain injury and post-traumatic stress disorder (PTSD).
The measure, which was introduced by Sen. Sarah Elfreth, cleared the House the week before. This comes after its unanimous approval in the Senate in March. This bill would establish a traumatic brain injury and PTSD alternative therapies fund.
In its text, the bill stipulates that the monies from the fund would be used to study alternative therapies that could be used by veterans with traumatic brain injuries and PTSD. The bill adds that the Department of Health in the state will be required to consult with the Walter Reed National Military Medical Center, Sheppard Pratt Hospital, the University of Maryland, Johns Hopkins University and the Department of Veterans Affairs.
The objective of these partnerships would be to find methods of improving access for veterans to alternative therapies for traumatic brain injuries and PTSD, as well as determine the effectiveness of said therapies. The department is required to submit a report to the governor containing initial recommendations and findings by Dec. 1, 2022.
The legislation also includes a separate deadline for recommendations and findings, which would be based on studies that were financed with the fund established by the measure. The measure’s text adds that these recommendations should focus on regulatory, legislative or budgetary changes to improve access to alternative therapies for veterans with traumatic-brain injuries and PTSD. It also asks that the governor include $1 million in an annual budget legislation for the fund, for the 2024 fiscal year.
Maryland is not the only state to advance a psychedelic reform measure in the country during this session, with legislators in Georgia recently passing a bipartisan legislation which demands that a study committee look into the therapeutic potential of psychedelics be formed. The committee will also be required to make recommendations for reform.
Last month, Utah Governor Spencer Cox also signed a measure to establish a task force to conduct research on psychedelics and give recommendations on the therapeutic potential of these drugs as well as possible regulations for their legal use. Additionally, a legislative committee passed a measure in Connecticut last month that would allow the state to offer eligible patients access to psychedelic-assisted therapy with drugs, including psilocybin and MDMA.
Already, companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) have established themselves as leading providers of ketamine treatments, and further research is ongoing to expand to other psychedelics as they become legal in different jurisdictions.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)